Pathogenic role of IL-17 in psoriasis and psoriatic arthritis

Andrea Chiricozzi

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics. Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.
Lingua originaleEnglish
pagine (da-a)9-20
Numero di pagine12
Stato di pubblicazionePubblicato - 2014


  • Arthritis
  • Atherosclerosis
  • Brodalumab
  • IL-17
  • Ixekizumab
  • Obesity
  • Psoriasis
  • Secukinumab


Entra nei temi di ricerca di 'Pathogenic role of IL-17 in psoriasis and psoriatic arthritis'. Insieme formano una fingerprint unica.

Cita questo